Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inspire Medical Systems, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding its product, Inspire V [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Inspire Medical common stock between August 6, 2024, and August 4, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Inspire Medical misrepresented the market demand for its sleep apnea device, Inspire V, and failed to disclose necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 5, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years [4].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations of Misleading Information - The lawsuit claims that Inspire provided repeated assurances about meeting all regulatory and commercial prerequisites for the Inspire V launch while promoting high demand, which was later revealed to be untrue [3][4]. - The complaint highlights that the actual launch of Inspire V was disastrous, with minimal initial demand attributed to customers being overstocked with the older Inspire IV devices [4][5]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers [5][6]. - The company noted that although the CPT code for Medicare patients was approved, software updates for claims processing did not take effect until July 1, delaying billing for procedures and leading centers to continue using the older Inspire IV [5][6]. Financial Consequences - As a result of the poor launch performance, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - Following this announcement, Inspire's stock price plummeted by approximately 32%, dropping $42.04 the next day [6].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. shareholders regarding potential breaches of fiduciary duties by certain officers of the company [1] Investigation Basis - A securities fraud class action complaint alleges that Inspire Medical misled investors about the launch of its key product, the Inspire V sleep apnea device, claiming it met all necessary conditions for a successful launch, while in reality, the launch faced significant issues [3] - The complaint states that demand for Inspire V was low due to customers having excess inventory of older devices, and that the company failed to ensure proper uptake by clinicians and payors, leading to delays in adoption [3] - Following the revelation of these issues on August 4, 2025, Inspire Medical's stock price dropped by 32%, resulting in a loss of over $1.5 billion in shareholder value [3] Actions for Shareholders - Current shareholders who have held Inspire Medical shares since before August 6, 2024, can pursue corporate reforms, seek the return of funds to the company, and obtain a court-approved incentive award at no cost [2][4]

Nov 7, 2025 6:00 PM Eastern Standard Time Rosen Law Firm Urges Inspire Medical Systems, Inc. (NYSE: INSP) Stockholders with Large Losses to Contact the Firm for Information About Their Rights Share NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period†). Inspire Medical is ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for allegedly misleading investors regarding the demand and launch of its implantable medical device for obstructive sleep apnea during the specified class period [1][3]. Summary by Sections Lawsuit Details - The lawsuit claims that during the class period from August 6, 2024, to August 4, 2025, Inspire Medical made false statements and failed to disclose poor demand for its product, leading to significant inventory issues and reluctance from providers to adopt the new treatment [3]. - The company allegedly assured investors that all necessary steps for a successful product launch were taken, which was later contradicted by the company's own admissions regarding incomplete training and onboarding at treatment centers [3]. Company Performance - On August 4, 2025, Inspire Medical disclosed that the launch of Inspire V was delayed due to many centers not completing required training and contracting, which affected the ability to bill for procedures [4]. - The company also revealed that the rollout faced poor demand due to excess inventory, resulting in a more than 80% reduction in its 2025 earnings guidance [4]. - Following this announcement, Inspire's share price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 [4]. Investor Actions - Investors who suffered losses during the class period have until January 5, 2025, to request lead plaintiff appointment in the class action lawsuit [1]. - The lead plaintiff appointment process allows investors with the largest financial losses to represent the class, influencing case strategy and settlement decisions [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. due to allegations of misleading investors regarding the launch of its Inspire V device, which has faced significant challenges and poor demand [1][2][3] Company Overview - Inspire Medical Systems, Inc. is a medical technology company that develops and manufactures an implantable device for treating obstructive sleep apnea, known as "Inspire" [1] Allegations and Issues - The complaint alleges that the launch of the Inspire V device was poorly executed, with providers holding excess inventory and being hesitant to adopt the new treatment [2] - Key failures cited include inadequate training for treatment centers, lack of essential IT systems, and unpreparedness for Medicare reimbursement at launch [2] Financial Impact - On August 4, 2025, Inspire announced a significant reduction in its 2025 earnings guidance by over 80%, dropping from a range of $2.20 to $2.30 per share to $0.40 to $0.50 per share [3] - Following this announcement, the company's stock price plummeted by $42.04 per share, a decline of more than 32%, resulting in a loss of $1.2 billion in market capitalization in a single day [3] - From a high of $216.71 per share on September 23, 2024, the stock has decreased by nearly 60%, erasing billions in market value [3] Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by January 5, 2026, to serve as lead plaintiff [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - Inspire Medical is facing a class action lawsuit due to alleged misleading statements regarding the launch of its Inspire V product, which reportedly encountered significant challenges and poor demand [3][4]. Summary by Sections Class Action Details - The class action is on behalf of investors who purchased securities between August 6, 2024, and August 4, 2025, with a deadline of January 5, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Allegations Against Inspire Medical - The lawsuit claims that Inspire Medical made false statements about the successful launch of Inspire V, which was actually hindered by poor demand and excess inventory at provider centers [3]. - It is alleged that many centers did not complete necessary training and onboarding, which delayed the launch and billing processes for Medicare patients [4]. Impact on Financial Guidance - Following the revelation of these issues on August 4, 2025, Inspire Medical reduced its 2025 earnings guidance by over 80%, leading to a more than 32% decline in its stock price [4].

Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK--(BUSINESS WIRE)--Faruq ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged misleading statements and failure to disclose critical issues regarding the launch of its Inspire V product, leading to significant investor losses [2][7]. Allegation Details - The lawsuit claims that during the Class Period, Inspire Medical made false statements about the successful launch of Inspire V, while in reality, the launch faced poor demand and significant inventory issues [7]. - It is alleged that many medical centers did not complete necessary training and onboarding, which hindered the rollout of Inspire V [7]. - The company reportedly reduced its 2025 earnings guidance by over 80% following the revelation of these issues, resulting in a more than 32% decline in the stock price on August 4, 2025 [7]. Next Steps - Investors who purchased Inspire Medical shares during the specified period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Inspire Medical business and prospects, resulting in its stock trading at inflated prices. ...